Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.

Our research results showed an increasing trend in PCSK9 inhibitors-related AKI reports since the drug’s market launch, reaching its peak in 2018, followed by a gradual decline, especially for evolocumab.

also in 63,971 other papers

We found that evolocumab is more likely to induce AKI in males (ROR = 1.40, 95% CI = 1.54–1.69), while alirocumab showed the opposite trend (ROR = 0.84, 95% CI = 0.59–1.20), although the latter did not reach statistical significance.

also in 111,027 other papers